Analyst Ratings For Cardiome Pharma Corporation (NASDAQ:CRME)
Today, Canaccord Genuity reiterated its Buy rating on Cardiome Pharma Corporation (NASDAQ:CRME) with a price target of $8.00.
There are 1 hold rating, 5 buy ratings on the stock.
The current consensus rating on Cardiome Pharma Corporation (NASDAQ:CRME) is Buy (Score: 2.83) with a consensus target price of $6.65 per share, a potential 41.49% upside.
Some recent analyst ratings include
- 7/17/2017-Canaccord Genuity Reiterated Rating of Buy.
- 12/22/2016-Leerink Swann initiated coverage with a Outperform rating.
- 11/9/2016-Bloom Burton Reiterated Rating of Buy.
- 10/12/2016-Mackie Reiterated Rating of Speculative Buy .
- 8/15/2016-Brean Capital Reiterated Rating of Buy.
- 8/14/2015-LB Securities Reiterated Rating of Buy.
Dividend information for Cardiome Pharma Corporation (NASDAQ:CRME)
.
Recent Trading Activity for Cardiome Pharma Corporation (NASDAQ:CRME)
Shares of Cardiome Pharma Corporation closed the previous trading session at 4.75 up +0.05 1.17% with 49,644 shares trading hands.